N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing and novel high value drugs with an unmet commercial or medical need. N4’s commercial strategy is to advance a pipeline of products through clinical proof of concept and then partner to take the products through the relevant regulatory pathway studies to regulatory approval. N4 has recently acquired the rights to a range of patents from OPAL IP to allow it to reformulate a wide range of existing drugs using a range of techniques. N4 also has two proprietary platform delivery system technologies allowing it to improve a vaccine's performance, the first a delivery system to improve cellular uptake of sub unit vaccines, the second to improve transfection efficiency of cancer vaccines and therapeutics. Its first product in development is a 'reformulated' version of Sildenafil (Viagra) aimed at improving the onset of action and maintaining an effective dose of the drug during the therapeutic window to make it last longer.